01

Growth Hormones in India: Market Growth, Clinical Applications, and the Role of Research Peptide Suppliers

  • 23 Aug, 2026

Introduction

Growth hormones play a pivotal role in human development, metabolism, and overall physiological function. In India, the landscape of growth hormone research, therapy, and supply is undergoing rapid transformation. With increasing awareness of hormonal disorders, rising diagnosis rates, and a growing emphasis on research and development, the growth hormone sector in India is witnessing unprecedented expansion.

This article explores the current state of growth hormones in India, examining market trends, clinical applications, regulatory frameworks, and the critical role that high-quality research peptide suppliers like CorePeptides India play in advancing scientific research across the country.

Understanding Growth Hormones

What Are Growth Hormones?

Human growth hormone (HGH), also known as somatotropin, is a peptide hormone produced by the pituitary gland. It is essential for growth during childhood and continues to play vital metabolic roles throughout adult life. Growth hormone stimulates growth, cell reproduction, and cell regeneration in humans. It is also involved in regulating body composition, muscle and bone growth, sugar and fat metabolism, and possibly heart function.

Types of Growth Hormones Available

In the Indian market, growth hormones are available in several forms:

  1. Recombinant Human Growth Hormone (rhGH): Synthetically produced using recombinant DNA technology, this is the most common form used in both clinical therapy and research.

  2. Natural Growth Hormone: Derived from biological sources, though less commonly used today.

  3. Synthetic Growth Hormone: Laboratory-created compounds designed to mimic the actions of natural growth hormone.

  4. Growth Hormone Releasing Peptides (GHRPs): Research peptides that stimulate the body's own growth hormone production.

The Indian Growth Hormone Market: A Booming Sector

Market Size and Growth Projections

The Indian growth hormone market is experiencing remarkable growth. According to recent data, the India human growth hormone market generated a revenue of USD 179.3 million in 2023 and is expected to reach USD 460.1 million by 2030, reflecting a compound annual growth rate (CAGR) of 14.4% from 2024 to 2030.

The broader Indian hormones market reached a value of Rs 3,812 crore in MAT October 2025, with 8% growth and a 5-year CAGR of 9%. This expansion is primarily driven by the hormone replacement therapy (HRT) and human growth hormone (HGH) segments.

Key Market Drivers

Several factors are fueling the growth of the growth hormone market in India:

  1. Increasing Awareness: Greater public and medical community awareness about hormonal disorders and their treatments.

  2. Rising Diagnosis Rates: Improved diagnostic capabilities and healthcare infrastructure leading to more cases being identified.

  3. Growing Prevalence of Growth Hormone Deficiencies: An increasing number of children and adults being diagnosed with growth hormone deficiency (GHD).

  4. Expanding Research Activities: India's emergence as a major hub for pharmaceutical and biotechnology research.

  5. Government Health Campaigns: Pediatric health initiatives and government-backed programs promoting early diagnosis and treatment.

Market Leaders and Emerging Players

The Indian hormones market remains anchored by large pharmaceutical companies such as Abbott, Macleods, GSK, Sun Pharma, and Zydus. Abbott led the market with 22% share and 19% growth, while Sun Pharma delivered a strong performance with 29% growth and a 19% five-year CAGR.

Notably, emerging specialty-driven companies are significantly outpacing industry averages. Companies such as Gufic Bioscience (449% growth, 82% CAGR), Centaur (114% growth, 44% CAGR), Troikaa (47% growth, 37% CAGR), and Ferring (25% growth, 19% CAGR) are demonstrating the power of innovation and differentiated hormone therapies.

Clinical Applications of Growth Hormones in India

Growth Hormone Deficiency (GHD)

Growth hormone deficiency is a well-established endocrinological cause of short stature and growth retardation. The incidence of GHD has been reported as 1 in 4,000 to 1 in 20,000 live births.

In India, short stature and growth retardation affect an estimated 2.8% to 7% of the pediatric population. Among children presenting for evaluation of short stature, approximately 4.3% are diagnosed with GHD.

Key clinical findings from Indian studies:

  1. Among 50 subjects in one study, 60% had idiopathic growth hormone deficiency and 26% had Turner's syndrome.

  2. rhGH treatment leads to significant improvement in anthropometry in Indian children, comparable with Western data.

  3. The most common hormonal abnormality in hypopituitarism patients is growth hormone deficiency, affecting approximately 70.6% of assessed patients.

Pediatric Applications

Growth hormone therapy is primarily administered as a daily subcutaneous injection in children with growth hormone deficiency. The therapy is used to treat:

  1. Idiopathic growth hormone deficiency

  2. Turner syndrome

  3. Prader-Willi syndrome

  4. Small for gestational age (SGA)

  5. Chronic renal insufficiency

  6. Other conditions causing short stature

Adult Applications

In adults, growth hormone therapy is used for:

  1. Adult growth hormone deficiency (often resulting from pituitary tumors or their treatment)

  2. Hormone replacement therapy

  3. Metabolic disorders

  4. Anti-aging and wellness applications (though this remains controversial and requires proper medical supervision)

Regulatory Framework for Growth Hormones in India

CDSCO Oversight

In India, peptides and growth hormones are regulated by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940 and Rules, 1945.

Classification System

Indian pharmaceutical scheduling categorizes growth hormones and related compounds as follows:

CategoryExamplesLegal StatusSchedule XSomatropin, Growth HormoneSpecial Control – Prescription RequiredSchedule HResearch Peptides (BPC-157, TB-500)Prescription OnlyApprovedGLP-1 Agonists (Liraglutide, Semaglutide)Prescription RequiredOTCCosmetic PeptidesOver-the-Counter

Recent Regulatory Developments

The CDSCO has been actively reviewing and updating regulations for growth hormone products:

  1. In October 2025, the Subject Expert Committee (SEC) under CDSCO recommended that Sun Pharmaceutical Industries conduct a Phase III clinical trial for its Somatropin liquid injection to generate India-specific safety and efficacy data.

  2. The CDSCO has mandated the use of the ONDLS portal for rDNA drug license applications, including those for human growth hormone products.

  3. India has established a named-patient pathway for accessing specialized growth hormone treatments like Skytrofa (lonapegsomatropin-tcgd) for pediatric patients.

Legal Access to Growth Hormones

Legal options for accessing growth hormones in India include:

  1. Consultation with registered medical practitioners (MBBS, MD)

  2. Licensed Indian pharmacies with valid prescriptions

  3. Hospital-based endocrinology departments

  4. Online pharmacies registered with state drug controllers

The Role of Research Peptides in Growth Hormone Studies

Growth Hormone-Related Research Peptides

Research peptides play a crucial role in advancing our understanding of growth hormone physiology, deficiency, and potential therapeutic applications. Key research peptides in this domain include:

  1. Growth Hormone Releasing Peptides (GHRPs): Stimulate the release of growth hormone from the pituitary gland.

  2. Growth Hormone Releasing Hormone (GHRH) Analogs: Mimic the action of natural GHRH.

  3. Sermorelin: A growth hormone-releasing hormone analog used in research.

  4. Tesamorelin: Used in growth hormone/endocrine research.

  5. Pralmorelin: A growth hormone-releasing peptide for research applications.

Why Quality Matters in Research Peptides

For researchers studying growth hormones and related pathways, the quality of research peptides is paramount. Key quality indicators include:

  1. Purity (>99% preferred): Higher purity ensures more reliable and reproducible results.

  2. HPLC Verification: High-Performance Liquid Chromatography confirms the purity and identity of the peptide.

  3. Certificate of Analysis (COA): Documentation proving the peptide's quality and specifications.

  4. Batch-to-Batch Consistency: Ensures reproducibility across experiments.

CorePeptides India: Your Trusted Partner for Research Peptides

When it comes to sourcing high-quality research peptides in India, CorePeptides India has emerged as a reliable and trusted supplier serving laboratories and institutional researchers nationwide.

About CorePeptides India

CorePeptides India is dedicated to providing premium research-grade peptides to the Indian scientific community. The company understands that scientific progress depends on the purity and consistency of every compound used in research.

Commitment to Quality

What sets CorePeptides India apart is its unwavering commitment to quality:

  1. >99% Purity: Every product meets or exceeds 99% purity standards.

  2. HPLC Verification: Each batch is verified using High-Performance Liquid Chromatography.

  3. Certificate of Analysis (COA): Every shipment includes a batch-specific COA, ensuring full traceability and transparency.

  4. Third-Party Testing: Products are tested by independent third-party laboratories.

Comprehensive Product Range

CorePeptides India offers a diverse catalog of research peptides, including:

  1. Growth hormone secretagogues

  2. GHRPs and GHRH analogs

  3. BPC-157

  4. Semaglutide and other GLP-1 agonists

  5. TB-500 and other research compounds

  6. Custom peptide blends

Reliable Supply Chain

Understanding the importance of product integrity, CorePeptides India maintains:

  1. Temperature-controlled cold-chain handling to preserve peptide stability

  2. Secure packaging to prevent damage during transit

  3. Express air network for fast pan-India delivery

  4. Secure encryption for all transactions

Why Researchers Choose CorePeptides India

  1. Transparency: Full disclosure of product specifications and testing results.

  2. Traceability: Batch-specific COAs with every order.

  3. Competitive Pricing: High-quality peptides at accessible prices.

  4. Fast Shipping: Quick, discreet delivery across India.

  5. Quality Assurance: Consistent quality across batches.

The Future of Growth Hormone Research in India

Emerging Trends

The growth hormone landscape in India is evolving rapidly, with several emerging trends:

  1. Personalized Medicine: Growing interest in tailored growth hormone therapies based on individual genetic profiles.

  2. AI in Treatment Planning: Machine learning is being explored to predict growth hormone therapy response in pediatric populations.

  3. Biosimilar Development: India is emerging as a hub for biosimilar growth hormone production.

  4. Research Expansion: Increasing investment in endocrinology research and peptide science.

  5. Global Integration: Indian peptide manufacturers are becoming major exporters to US, EU, and other markets.

Challenges and Opportunities

While the growth hormone sector in India presents significant opportunities, challenges remain:

  1. Awareness Gap: Many cases of growth hormone deficiency remain undiagnosed.

  2. Access Issues: Rural populations often lack access to specialized endocrinology care.

  3. Regulatory Compliance: Navigating CDSCO regulations requires expertise and diligence.

  4. Quality Variation: Quality varies significantly between manufacturers.

The Role of Quality Suppliers

As India's research capabilities expand, the role of reliable suppliers like CorePeptides India becomes increasingly critical. By providing consistently high-quality, verifiable research peptides, CorePeptides India supports:

  1. Academic Research: Universities and research institutions conducting fundamental growth hormone studies.

  2. Pharmaceutical Development: Companies developing new growth hormone therapies.

  3. Clinical Research: Studies investigating growth hormone deficiency and treatment outcomes.

  4. Biotechnology Innovation: Companies exploring novel applications of growth hormone peptides.

Conclusion

The growth hormone sector in India is experiencing unprecedented growth, driven by increasing awareness, rising diagnosis rates, and expanding research activities. With the market projected to reach USD 460.1 million by 2030, India is positioning itself as a major player in the global growth hormone landscape.

For researchers and institutions working in this exciting field, access to high-quality research peptides is essential. CorePeptides India stands ready to support the Indian scientific community with premium research-grade peptides, comprehensive quality documentation, and reliable supply chain solutions.

Whether you are investigating growth hormone deficiency, exploring new therapeutic applications, or conducting fundamental endocrinology research, CorePeptides India provides the quality, transparency, and reliability that serious research demands.

Disclaimer: This article is for informational and educational purposes only. Growth hormones and related peptides are regulated substances in India. Always consult with qualified medical professionals and adhere to all applicable laws and regulations. Research peptides are intended for laboratory use only and are not approved for human consumption or therapeutic use without proper authorization.

Write a comment ...

Write a comment ...